UK pharmaceutical companies honoured in Queen's Awards

Published: 21-Apr-2003
Analysis

Among the companies awarded the UK's highest honour for business success - a Queen's Award for Enterprise - are a drug manufacturer, a pharmaceutical marketing consultancy, a manufacturer and distributor of vitamin supplements and nutraceuticals, and a company whose superconducting magnet has opened up new possibilities for life science and drug discovery research.


Among the companies awarded the UK's highest honour for business success - a Queen's Award for Enterprise - are a drug manufacturer, a pharmaceutical marketing consultancy, a manufacturer and distributor of vitamin supplements and nutraceuticals, and a company whose superconducting magnet has opened up new possibilities for life science and drug discovery research.

Receiving awards for international trade are Cyton Biosciences, Penn Pharmaceutical Services, Pfizer and Vitabiotics; Controlled Therapeutics (Scotland), Oxford Instruments Superconductivity and Tripos Receptor Research are being given Queen's Awards for Innovation.

  • Companies:
  • Oxford Instruments
See more

You may also like

Analysis

A new generation of mechanical surface testing platforms

Read more
The Step series allows high precision readings and easy transitioning between methods

Trending Articles

  1. Shimadzu’s new Nexera XS inert UHPLC The Nexera XS inert achieves reduced sample loss and excellent peak shape with reproducibly high sensitivity, high-quality and reliable data
  2. Abzena launches EpiScreen 2.0 to assist the development of complex biologics and bioconjugates The updated platform delivers an advanced range of immune response measurements, while also providing information on mechanism-of-action and specificity
  3. Improving the analysis of RNA medicines: what to expect in 2024 In vitro transcribed (IVT) RNA development has advanced since the first messenger RNA (mRNA) vaccines to prevent COVID-19 entered the market in 2020. Now the focus of similar drug candidates is on other prophylactic vaccines to prevent infectious diseases, including influenza and respiratory syncytial virus (RSV), and therapeutic drugs that might soon be used to treat cancer and other diseases
  4. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  5. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

You may also like

Analysis

A new generation of mechanical surface testing platforms

The Step series allows high precision readings and easy transitioning between methods
Research & Development

Abzena launches EpiScreen 2.0 to assist the development of complex biologics and bioconjugates

The updated platform delivers an advanced range of immune response measurements, while also providing information on mechanism-of-action and specificity
Research & Development

New automated tissue dissociation systems

Introducing the new Singulator series (100 and 200)
Analysis

Beckman introduces novel CE-Marked Hepatitis Assays at ESCMID Global

The HBsAg high positive algorithm eliminates the need for repeat and confirmatory testing for samples ≥ 100.00 S/CO
Analysis

Titan Enterprises’ 800-series turbine flow meters provide a low-cost solution for the pharmaceutical industry

Titan's flowmeters can assist in accurate batch delivery and dispensing systems for low viscosity liquids for incorporation in ingestible pharmaceutical products
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Analysis

IMPACT CKD model reveals the escalating toll of chronic kidney disease

The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Subscribe now